Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Официальное название

Tirofiban With Sequential Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone in Mild Acute Ischemic Stroke (TiMIS): A Multicenter, Open-Label, Blinded-Endpoint, Parallel-Controlled, Randomized Clinical Trial

Обзор

This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

Подробное описание

Although dual antiplatelet therapy (DAPT) reduces stroke recurrence and disability risks, its efficacy is limited in patients with mild ischemic stroke (NIHSS ≤5), among whom early neurological deterioration (END) and poor functional outcomes are frequently observed. Notably, intravenous thrombolysis is not more effective than DAPT for mild stroke management. Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, has shown potential efficacy in mild-to-moderate ischemic stroke, but robust evidence specific to mild stroke remains lacking. This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

Вмешательства

• Препарат Tirofiban+Oral Dual Antiplatelet Therapy
  Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)
• Препарат Oral Dual Antiplatelet Therapy
  Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)

Первичные конечные точки

• Proportion of excellent functional outcomes (mRS 0-1) [Срок оценки: 90 days]

Вторичные конечные точки (10)

• Incidence of early neurological deterioration [Срок оценки: 72 hours]
• Incidence of early neurological improvement [Срок оценки: 72 hours]
• Change in National Institutes of Health Stroke Scale score from baseline [Срок оценки: 7 days]
• Proportion of good functional outcomes (mRS 0-2) [Срок оценки: 90 days]
• Distribution of mRS scores [Срок оценки: 90 days]
• Incidence of schemic stroke [Срок оценки: 90 days]
• Incidence of major adverse cardiovascular events [Срок оценки: 90 days]
• Rate of symptomatic intracerebral hemorrhage [Срок оценки: 7 days]
• Rate of all-cause mortality [Срок оценки: 90 days]
• Rate of major bleeding events [Срок оценки: 90 days]

Критерии участия

Критерии включения

• Age: 18-80 years old.
• Acute mild non-cardioembolic stroke.
• NIHSS score ≤5.
• Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours.
• The investigational drug can be administered within 48 hours of symptom onset.
• Signed informed consent by the patient or legally authorized representative.

Критерии исключения

• Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
• Intracranial hemorrhage confirmed by imaging.
• Pre-stroke modified Rankin Scale (mRS) score ≥2.
• Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%.
• History of primary intracerebral hemorrhage.
• History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage).
• Untreated or inadequately treated intracranial aneurysm or vascular malformation.
• Major systemic bleeding within 30 days.
• Active bleeding, including laboratory evidence of coagulopathy (platelet count <100 × 10⁹/L, activated partial thromboplastin time >50 seconds, or international normalized ratio >1.7), or treatment with direct oral anticoagulants within the preceding 48 hours.
• Major surgery within 14 days.
• Persistently elevated blood pressure (systolic >180 mmHg or diastolic >110 mmHg) despite treatment.
• Baseline platelet count <100 × 10⁹/L.
• Severe renal dysfunction (glomerular filtration rate <30 mL/min or serum creatinine >220 μmol/L \[2.5 mg/dL\]).
• Known allergy or contraindication to tirofiban or aspirin.
• Current pregnancy or lactation.
• Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter).
• Any terminal illness with life expectancy <6 months.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Лечение

Центры проведения

Китай · 18 центров

• Suzhou Municipal Hospital of Anhui Province — Сучжоу
• Second Hospital of Hebei Medical University — Shijiazhuang
• Taikang Xian People's Hospital — Zhoukou
• WuYuan County People's Hospital — Bayan Nur
• Huai'an First People's Hospital — Huai'an
• Jiangsu Province (Suqian) Hospital — Suqian
• Second Affiliated Hospital of Soochow University — Сучжоу
• Affiliated Jiangsu Shengze Hospital of Nanjing Medical University — Сучжоу
• … и ещё 10 центров

Публикации

• Xu J, Peng H, Zhu Y, Xu F, Zhu L, Yang J, Kang T, Wang S, Yu X, Liu J, Wang P, Zhang M, Liu CF, Cao Y, Shi J. Tirofiban with sequential dual antiplatelet therapy in mild acute ischemic stroke (TiMIS): protocol for a multicenter, randomized controlled trial. Ann Med. 2026 Dec;58(1):2644698. doi: 10.1080/07853890.2026.2644698. Epub 2026 Mar 15. PMID 41834238

Идентификаторы

NCT: NCT07095790 · LK2025063 · 2024yb48

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗